News stories about Acasti Pharma (NASDAQ:ACST) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Acasti Pharma earned a news impact score of 0.16 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.9260029976127 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Separately, ValuEngine upgraded Acasti Pharma from a “sell” rating to a “hold” rating in a report on Monday, November 20th.

Acasti Pharma (NASDAQ ACST) traded down $0.09 on Wednesday, reaching $1.23. The company had a trading volume of 477,700 shares, compared to its average volume of 182,395. Acasti Pharma has a one year low of $1.11 and a one year high of $3.36. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.55 and a quick ratio of 4.55.

TRADEMARK VIOLATION WARNING: “Acasti Pharma (ACST) Receives Coverage Optimism Score of 0.16” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at

Acasti Pharma Company Profile

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG).

Insider Buying and Selling by Quarter for Acasti Pharma (NASDAQ:ACST)

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with's FREE daily email newsletter.